Sponsor Hep B foundation

Published on 03/06/2019

ENYO Pharma takes part to the research against Hepatitis B with the development of its FXR agonist EYP001 and support the research is this field by becoming one of the sponsor of the Hep B Foundation which is “a national nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide”

Read next in 'Latest news'

• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
• New publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters